A5091305831- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Pelvic floor disorders treatments
- Urinary Bladder and Prostate Research
- Bladder and Urothelial Cancer Treatments
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Urologic and reproductive health conditions
- Renal and related cancers
- Renal cell carcinoma treatment
- Ureteral procedures and complications
- Urinary Tract Infections Management
- Anorectal Disease Treatments and Outcomes
- Cancer, Lipids, and Metabolism
- Pediatric Urology and Nephrology Studies
- Surgical Simulation and Training
- Cancer Research and Treatments
- Multiple and Secondary Primary Cancers
- Renal and Vascular Pathologies
- Kidney Stones and Urolithiasis Treatments
- Radiopharmaceutical Chemistry and Applications
- Hormonal and reproductive studies
- Cancer Genomics and Diagnostics
- Renal Transplantation Outcomes and Treatments
- Pelvic and Acetabular Injuries
Hospital Clínico San Carlos
2016-2025
Universidad Complutense de Madrid
2006-2025
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos
2015-2023
Hospital Clínico Universitario de Valencia
2010-2012
Urology Team
2011
Hospital Universitario de Fuenlabrada
2009
To evaluate the feasibility and long-term outcomes of our initial series robot-assisted laparoscopic sacrocolpopexy.We conducted a prospective analysis robotic sacrocolpopexy.patients with grades III IV cystocele or other symptomatic pelvic organ prolapse. We performed transperitoneal four-trocar technique Da Vinci system using two polypropylene meshes for fixation to sacral promontory. The primary outcome was recurrence; secondary included operating room time, blood loss, conversion open...
We estimate the annual incidence of bladder cancer in Spain and describe clinical profile patients with enrolled a population based study.Using structure Spanish National Health System as basis, 2011 AEU (Spanish Association Urology) conducted this study representative sample from 26 public hospitals reference 10,146,534 inhabitants, comprising 21.5% population.A total 4,285 episodes were diagnosed, which 2,476 (57.8%) new cases 1,809 (42.2%) recurrence, representing an estimated 11,539...
Bladder cancer occurs in the epithelial lining of urinary bladder and is amongst most common types humans, killing thousands people a year. This paper based on hypothesis that use clinical histopathological data together with information about concentration various molecular markers patients useful for prediction outcomes design treatments nonmuscle invasive carcinoma (NMIBC). A population 45 new diagnosis NMIBC was selected. Patients benign prostatic hyperplasia (BPH), muscle (MIBC), situ...
Despite good long-term outcomes of kidney transplants from controlled donation after circulatory death (DCD) donors, there are few uncontrolled DCD (uDCD) programs. This longitudinal study compares for all uDCD (N = 774) and brain (DBD) 613) performed 1996 to 2015 at our center. DBD were divided into those standard-criteria (SCD) 366) expanded-criteria 247) brain-dead donors (ECD). One-, 5-, 10-year graft survival rates 91.7%, 85.7%, 80.6% SCD; 86.0%, 75.8%, 61.4% ECD; 85.1%, 78.1%, 72.2%...
Background and Objectives: Prostate cancer (PCa) is a common disease with significant amount of patients first diagnose locoregional or distant metastases. This why it essential to have imaging tests sufficient sensitivity specificity. Having traditional methods recognized limitations, PET-PSMA born as weapon revolutionize the management PCa. Material Methods: We made comprehensive literature review from August October 2023 using databases also key clinical guidelines topic, focusing on...
Background and Objectives: Prostate cancer (PCa) is a common disease, with significant number of patients initially diagnosed locoregional or distant metastases. This why it essential to have imaging tests sufficient sensitivity specificity. Given the recognized limitations traditional methods, PSMA-PET has emerged as promising tool that may revolutionize management PCa. Material Methods: We conducted comprehensive literature review from August October 2023 using databases key clinical...
Pretreatment assessment of patients diagnosed with localized prostate cancer (PCa) is essential for therapeutic decision-making. Currently available staging systems based on prostate-specific antigen (PSA), Gleason score, and clinical stage allow determining the prognostic characteristics these patients. Several studies have evaluated preoperative use density (PSAD) as a factor further risk stratification. To date, role PSAD in this setting still an object debate.